Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LUNG

LUNG - Pulmonx Corp Stock Price, Fair Value and News

$1.77+0.02 (+1.14%)
Market Closed

83/100

LUNG

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

83/100

LUNG

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.78

Target 3M

$2.22

Target 6M

$2.5

LUNG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LUNG Price Action

Last 7 days

-4.8%

Last 30 days

-20.6%

Last 90 days

0.6%

Trailing 12 Months

-70.7%

LUNG RSI Chart

LUNG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LUNG Valuation

Market Cap

73.0M

Price/Earnings (Trailing)

-1.29

Price/Sales (Trailing)

0.8

EV/EBITDA

-0.63

Price/Free Cashflow

-2.24

LUNG Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.78

Target 3M

$2.22

Target 6M

$2.5

LUNG Fundamentals

LUNG Revenue

Revenue (TTM)

91.7M

Rev. Growth (Yr)

5.47%

Rev. Growth (Qtr)

-9.88%

LUNG Earnings

Earnings (TTM)

-56.8M

Earnings Growth (Yr)

1.32%

Earnings Growth (Qtr)

8.01%

LUNG Profitability

Operating Margin

100.00%

EBT Margin

-61.39%

Return on Equity

-94.54%

Return on Assets

-41.04%

Free Cashflow Yield

-44.58%

LUNG Investor Care

Shares Dilution (1Y)

4.45%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202587.5M90.5M91.7M0
202473.0M76.6M79.3M83.8M
202357.4M60.7M64.8M68.7M
202250.0M51.7M51.9M53.7M
202133.4M41.9M44.5M48.4M
202035.4M31.7M33.3M32.7M
201923.2M26.3M29.4M32.6M
201800020.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Pulmonx Corp

LUNG
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://pulmonx.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES269

Pulmonx Corp Frequently Asked Questions

LUNG is the stock ticker symbol of Pulmonx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pulmonx Corp is 73.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LUNG's fair value in chart for subscribers.

The fair value guage provides a quick view whether LUNG is over valued or under valued. Whether Pulmonx Corp is cheap or expensive depends on the assumptions which impact Pulmonx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUNG.

As of Wed Jan 28 2026, LUNG's PE ratio (Price to Earnings) is -1.29 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUNG PE ratio will change depending on the future growth rate expectations of investors.